Cell & Gene Therapies hold incredible potential for improving – if not saving – human lives. These CGT’s have been called “living drugs” and can heal diseased organs and – we hope – fight diseases that currently have no cure.  Because of these incredible possibilities, related research and development is growing exponentially around the globe, with increasing numbers of complex clinical trials – complex because they require complicated and precisely-timed pickup and delivery of specimens and deliveries. A single hiccup anywhere in terms of pickup, drop-off, temperature, contamination – anything – can cause significant challenges. So what, exactly, does it take to set up a robust Cell & Gene Therapy supply chain? What should manufacturers, labs, pharmaceutical and biotech companies, and logistics providers consider?  Mike Sweeney can explain. Mike is Global Head of Strategy for CGT and Direct to Patient products (CGT and DTP) at QuickSTAT Global Life Science Logistics. He joins me now to discuss why – for CGT Supply Chains – planning in advance is the best medicine. For more information on clinical trial logistics, visit our website at quickstat.com.